Zeo ScientifiX Files Q2 10-Q

Ticker: ZEOX · Form: 10-Q · Filed: Jun 14, 2024 · CIK: 1557376

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

Zeo ScientifiX (formerly Organicell) filed its 10-Q for April 30, 2024. Check financials.

AI Summary

Zeo ScientifiX, Inc. filed its 10-Q for the period ending April 30, 2024. The company, formerly known as Organicell Regenerative Medicine, Inc., is in the biological products sector. The filing covers financial information and operational updates for the quarter.

Why It Matters

This filing provides investors with the latest financial performance and operational details for Zeo ScientifiX, Inc., crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information which can reveal significant risks or opportunities, but without specific financial performance data in this snippet, a definitive risk level is hard to assign.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Zeo ScientifiX, Inc.?

Zeo ScientifiX, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.

When was Zeo ScientifiX, Inc. previously known by another name?

Zeo ScientifiX, Inc. was formerly known as Organicell Regenerative Medicine, Inc., with a name change date of 20180625.

What is the fiscal year end for Zeo ScientifiX, Inc.?

The company's fiscal year ends on October 31st (1031).

Where is Zeo ScientifiX, Inc. located?

The company's business and mailing address is 3321 COLLEGE AVENUE, SUITE 246, DAVIE, FL 33314.

What is the SEC file number for Zeo ScientifiX, Inc.?

The SEC file number for Zeo ScientifiX, Inc. is 000-55008.

Filing Stats: 4,440 words · 18 min read · ~15 pages · Grade level 16.2 · Accepted 2024-06-14 16:15:30

Key Financial Figures

Filing Documents

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 25 Item 4.

Controls and Procedures

Controls and Procedures. 25 PART II OTHER INFORMATION Item 1. Legal Proceedings. 26 Item 1A. Risk Factors. 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 26 Item 3. Defaults Upon Senior Securities. 26 Item 4. Mine Safety Disclosures. 26 Item 5. Other Information. 26 Item 6. Exhibits. 27

– FINANCIAL INFORMATION

Part I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Zeo ScientifiX, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts rounded to the nearest thousand except share amounts) April 30, 2024 (Unaudited) October 31, 2023 ASSETS Current Assets Cash $ 746,000 $ 1,756,000 Accounts receivable, net of allowance for bad debts 60,000 18,000 Other receivables 12,000 12,000 Prepaid expenses 328,000 106,000 Inventories 272,000 310,000 Total Current Assets 1,418,000 2,202,000 Property and equipment, net 514,000 573,000 Security deposits - 7,000 TOTAL ASSETS $ 1,932,000 $ 2,782,000 LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses $ 1,934,000 $ 2,612,000 Advances payable to former officer 221,000 221,000 Finance lease obligations 5,000 23,000 Convertible promissory note, net of debt discount of $ 56,000 and $ 68,000 669,000 657,000 Deferred revenue 792,000 497,000 Total Current Liabilities 3,621,000 4,010,000 Long term finance lease obligations 11,000 13,000 Total Liabilities 3,632,000 4,023,000 Commitments and contingencies Shares Subject To Possible Redemption Series C Preferred Stock, $ 0.001 par value, 100 shares authorized; 100 and 100 shares issued and outstanding, respectively - - Stockholders' Deficit Common stock, $ 0.001 par value, 2,500,000,000 shares authorized; 6,332,419 and 7,283,483 shares issued and outstanding, respectively 6,000 7,000 Additional paid-in capital 58,241,000 56,260,000 Accumulated deficit ( 59,947,000 ) ( 57,508,000 ) Total Stockholders' Deficit ( 1,700,000 ) ( 1,241,000 ) TOTAL LIABILITIES, SHARES SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS' DEFICIT $ 1,932,000 $ 2,782,000 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Zeo ScientifiX, Inc. CONDENSED CONS

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing